 |
 
|
 |
 |
| |
 |
|
|
| ||||||||||
|
|
|
|
|
|
|
||||
| ||||||||||
 |
|
|
|
Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation and the title of the report in the subject line of e-mail. Recommendations of the U.S. Public Health Service Task Force on the Use of Zidovudine to Reduce Perinatal Transmission of Human Immunodeficiency VirusExecutive Committee and U.S. Public Health Service Task Force On June 6, 1994, the U.S. Public Health Service convened a workshop in Bethesda, Maryland, to develop recommendations for the use of zidovudine to reduce the risk for perinatal transmission of human immunodeficiency virus (HIV). The recent results of AIDS Clinical Trials Group Protocol 076, a controlled clinical trial sponsored by the National Institutes of Health in collaboration with the National Institute of Health and Medical Research and the National Agency of Research on AIDS in France, indicate that zidovudine administered to a selected group of HIV-infected women and their infants can reduce the risk for perinatal transmission of HIV by approxi- mately two-thirds. The implications of these results for use of zidovudine in HIV-infected pregnant women and neonates were discussed at the workshop. The following persons participated in the workshop and either served as the Executive Committee writing group that developed the recommendations or were members of the U.S. Public Health Service Task Force on the Use of Zidovudine to Reduce Perinatal HIV Transmission. Executive Committee Howard L. Minkoff, M.D. (co-chair) Wade Parks, M.D. (co-chair) State University of New York New York University School of Brooklyn, NY Medicine New York, NY Arlene D. Bardeguez, M.D. New Jersey Medical School Paul Meier, Ph.D. Newark, NJ Columbia University New York, NY Yvonne J. Bryson, M.D. University of California at Angus Nicoll, M.D. Los Angeles Communicable Disease Surveillance Los Angeles, CA Centre London, England Isaac Delke, M.D. University of Florida College of Mary J. O'Sullivan, M.D. Medicine University of Miami Jacksonville, FL Miami, FL Clemente Diaz, M.D. Sallie M. Perryman University of Puerto Rico New York State Department of Health School of Medicine New York, NY San Juan, PR Gwendolyn B. Scott, M.D. Joep M.A. Lange, M.D. University of Miami School of World Health Organization Medicine Geneva, Switzerland Miami, FL Michael K. Lindsay, M.D., M.P.H. Diane W. Wara, M.D. Emory University University of California at Atlanta, GA San Francisco San Francisco, CA Mary A. Young, M.D. Georgetown University Medical Center Carmen D. Zorrilla, M.D. Washington, DC University of Puerto Rico School of Medicine San Juan, PR U.S. Public Health Service Task Force on the Use of Zidovudine To Reduce Perinatal Transmission of Human Immunodeficiency Virus Lynne M. Mofenson, M.D. (chair) David Lanier, M.D. National Institutes of Health Agency for Health Care Policy Bethesda, MD and Research Rockville, MD James Balsley, M.D., Ph.D. National Institutes of Health Frances E. Page, B.S.N., M.P.H. Bethesda, MD Office of National AIDS Policy Washington, DC Patricia S. Fleming Office of the Secretary Martha F. Rogers, M.D. U.S. Department of Health and Centers for Disease Control Human Services and Prevention Washington, DC Atlanta, GA Helene D. Gayle, M.D., M.P.H. Patricia Salomon, M.D. Centers for Disease Control Health Resources and Services and Prevention Administration Washington, DC Rockville, MD Steven Gitterman, M.D., Ph.D. Food and Drug Administration Rockville, MD The material in this report was prepared for publication by: Lynne Mofenson, M.D. Pediatric, Adolescent, and Maternal AIDS Branch Center for Research for Mothers and Children National Institute of Child Health and Human Development National Institutes of Health James Balsley, M.D., Ph.D. Division of Acquired Immunodeficiency Syndrome National Institute of Allergy and Infectious Diseases National Institutes of Health in collaboration with Robert J. Simonds, M.D. Martha F. Rogers, M.D. Robin R. Moseley, M.A.T. Division of HIV/AIDS National Center for Infectious Diseases Summary These recommendations update the interim guidelines (1) developed by the U.S. Public Health Service for the use of zidovudine (ZDV) to reduce the risk for perinatal transmission of human immunodeficiency virus (HIV) infection. The recently reported results of AIDS Clinical Trials Group Protocol 076 demonstrated that ZDV administered to a selected group of HIV- infected pregnant women and their infants can reduce the risk for perinatal HIV transmission by approximately two-thirds. The regimen used in this trial included antenatal oral administration of ZDV beginning at 14-34 weeks of gestation and continuing throughout pregnancy, followed by intra- partum intravenous ZDV and postnatal oral administration of ZDV to the infant for 6 weeks after delivery. This document summarizes the results of the trial, discusses limita- tions in the interpretation of the results, reviews the potential long-term adverse effects of this ZDV regimen for infants and women, and provides recommendations for the use of ZDV to reduce perinatal transmission and for medical monitoring of pregnant women and infants receiving this therapy. Because the clinical status of many HIV-infected women may differ from that of the women in this trial, the recommendations should be tailored to each woman's clinical situation. The potential benefits, unknown long-term effects, and gaps in knowledge about her specific clinical situation must be discussed with the woman. This information is intended to provide a basis for discussion between the woman and her health-care provider so that the woman can weigh the risks and benefits of such therapy and make informed decisions about her treatment. INTRODUCTION Worldwide, perinatal (i.e., mother-to-infant) transmission accounts for most human immunodeficiency virus (HIV) infections among children. In the United States, approximately 7,000 infants, 1,000-2,000 of whom are HIV infected, are born to HIV-infected women each year (2). In the United States, HIV is currently the seventh leading cause of death in children 1-4 years of age (3) and the fourth among women 25-44 years of age (4). The ideal approach to reducing perinatal transmission is to prevent HIV infection among women. However, despite ongoing efforts to provide education about HIV prevention, the incidence of infections among women of reproductive age in the United States is increasing in some areas (2). In the United States, where safe alternatives to breast milk are available, HIV-infected women are advised to refrain from breastfeeding to avoid postnatal transmission of HIV to their infants (5). However, refraining from breastfeeding will not prevent transmission occurring in utero or intrapartum, and strategies to reduce transmission during these periods are being evaluated. The recently reported interim results of the Acquired Immunodeficiency Syndrome (AIDS) Clinical Trials Group (ACTG) Protocol 076, a clinical trial sponsored by the National Institutes of Health in collaboration with the National Institute of Health and Medical Research and the National Agency of Research on AIDS in France, indicate that zidovudine (ZDV) administered to a selected group of HIV-infected pregnant women and their infants can reduce the risk for perinatal HIV transmission by approximately two-thirds (1,6). This use of ZDV has the potential to substantially reduce the rate of perinatal transmission, which would reduce overall child mortality. However, the results of this study are directly applicable only to HIV- infected women with characteristics similar to those of the women who entered the study, and the long-term risks of ZDV used in this manner are not known. On June 6-7, 1994, the U.S. Public Health Service convened a workshop, "Use of ZDV to Prevent Perinatal HIV Transmission (ACTG Protocol 076): Workshop on Implications for Treatment, Counseling, and HIV Testing." The medical, scientific, public health, and legal communities and interested professional, community, and advocacy organizations were represented. The workshop addressed two issues related to the results of ACTG Protocol 076:
This report summarizes the conclusions of the workshop with regard to the use of ZDV to reduce perinatal transmission, provides recommendations for treatment options for HIV-infected pregnant women and their newborns and medical monitoring for pregnant women and neonates receiving ZDV, and discusses issues related to long-term follow-up of women and their children who have received ZDV. BACKGROUND Summary of Results of ACTG Protocol 076 On February 21, 1994, the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute of Child Health and Human Development announced the interim results of a randomized, multicenter, double-blind, placebo-controlled clinical trial, ACTG Protocol 076. Eligible participants were HIV-infected pregnant women at 14-34 weeks of gestation who had received no antiretroviral therapy during their current pregnancy, had no clinical indications for antepartum antiretroviral therapy, and had CD4+ T-lymphocyte counts greater than or equal to 200/uL at the time of entry into the study (Box 1) Table_B1. The study began in April 1991; as of December 20, 1993, the time of the interim analysis, 477 women had been enrolled and 421 infants born. The racial/ethnic distri- bution of the HIV-infected women enrolled in the trial was similar to that of the total population of HIV-infected women in the United States. Enrolled women were assigned randomly to receive a regimen of either ZDV or placebo. The ZDV regimen included oral ZDV initiated at 14-34 weeks of gestation and continued throughout the pregnancy, followed by intra- venous ZDV during labor and oral administration of ZDV to the infant for 6 weeks after delivery (Box 2) Table_B2. The placebo regimen was adminis- tered identically. Blood specimens were obtained for HIV culture from all infants at birth and at 12, 24, and 78 weeks of age. A positive viral culture was considered indicative of HIV infection. Sera from the infants at 15 and 18 months of age also were tested for HIV antibody. The Kaplan-Meier method (7) was used to estimate the rate of perinatal transmission at 18 months of age among the 364 children whose HIV infection status was known on the basis of culture and who therefore were included in the interim analysis. The estimated transmission rate was 25.5% among the 184 children in the placebo group (95% confidence interval {CI}=18.4%- 32.5%), compared with 8.3% among the 180 children in the ZDV group (95% CI=3.9%-12.8%). The difference in the estimated transmission rate between the two groups was statistically significant (p=0.00006). ZDV treatment did not appear to delay the diagnosis of HIV infection. Observed toxicity specifically attributable to ZDV was minimal among the women in this study. Adverse effects such as anemia, neutropenia, thrombocytopenia, and liver chemistry abnormalities were reported as frequently among women receiving placebo as among women receiving ZDV. Six women -- three in each treatment group -- discontinued therapy because of toxicity attributed to the study drug. The women were evaluated at 6 weeks and 6 months postpartum. A statistically significant increase in CD4+ T-lymphocyte count from baseline to 6 weeks postpartum was observed for women in both ZDV and placebo treatment groups; this increase was greater among women in the ZDV group. At 6 months postpartum, the CD4+ T-lymphocyte counts for both groups had decreased to similar levels. CD4+ T-lymphocyte counts decreased to less than 200/uL in only four women, including one receiving ZDV and three receiving placebo. No women died during the study. Serial sonographic evaluations for fetal growth and amniotic fluid volume as conducted in the study (at entry and every 4 weeks from 28 weeks of gestation until delivery) demonstrated no differences between preg- nancies in women who had received placebo or ZDV. Birth parameters (gesta- tional age; birth weight, length, and head circumference; and Apgar scores) were similar among infants born to women in either group. The median birth weight was 3,160 g (range: 1,040-5,267 g), and the median gestational age at birth was 39 weeks (range: 27-43 weeks). No statistically significant difference was observed between the ZDV and placebo groups in the number of infants with birth weight less than 2,500 g, who were small or large for gestational age, or who were born prematurely. The occurrence of major or minor congenital abnormalities was approximately equal between the two groups, and no pattern in the type of abnormalities was observed. The infants in the study tolerated the ZDV therapy well. The only adverse effect observed more frequently among infants in the ZDV treatment group was mild, transient anemia. Hemoglobin values for infants in the group receiving ZDV were lower than for the group receiving placebo, with a maximum mean difference of 1 gm/dL occurring at 3 weeks of age. The lowest mean hemoglobin value in infants receiving ZDV occurred at 6 weeks of age and resolved without therapy for anemia after the infants had completed the ZDV treatment. The hemoglobin values of infants receiving ZDV were similar to those of placebo recipients by 12 weeks of age. The incidence of neutropenia and serum chemistry abnormalities was similar between ZDV and placebo groups of infants, and no difference in the pattern of chemistry abnormalities was observed. Based on these interim findings, NIAID accepted the recommendation of its independent data and safety monitoring board to terminate enrollment into the trial and to offer ZDV to women in the placebo group who had not yet delivered and to their infants up to 6 weeks of age. * Follow-up of patients enrolled in the study is ongoing. Limitations in Interpretation and Extrapolation of ACTG Protocol 076 Results This clinical trial demonstrated that the ACTG Protocol 076 ZDV regimen can substantially reduce perinatal HIV transmission. However, several important limitations should be noted. First, perinatal HIV transmission was still observed despite drug therapy. Second, the efficacy of this therapy is unknown for HIV-infected pregnant women who have advanced disease, who have received prior antiretroviral therapy, or who have ZDV- resistant virus strains. Third, although the ZDV regimen used in this trial was not associated with serious short-term adverse effects, such effects may be observed when this use of ZDV becomes more widespread. Fourth, the long-term risks for the child associated with exposure to ZDV in utero and early infancy have not been determined. Fifth, it is not known if use of ZDV during pregnancy will affect the drug's efficacy for the woman when it becomes clinically indicated for her own health. Further complicating the incorporation of this ZDV regimen into clinical practice is the fact that some HIV-infected women seek medical care late in pregnancy or when they are already in labor, when the full ZDV regimen used in ACTG Protocol 076 cannot be administered. Moreover, many pregnant women are not aware that they are HIV infected, are not tested before or during pregnancy, and remain undiagnosed. As a result, they do not receive information about therapy that could reduce the risk for HIV transmission to their infants. Potential Long-Term Adverse Effects of ZDV Administered During Pregnancy The long-term effects of ZDV treatment during pregnancy solely to reduce perinatal transmission or of fetal and neonatal exposure to ZDV are not known. ZDV is a nucleoside analog that inhibits HIV replication by interfering with HIV RNA-dependent DNA polymerase. ZDV triphosphate also can inhibit human cellular DNA polymerases, but only at concentrations much higher than those required to inhibit HIV polymerase. However, gamma DNA polymerase, which is required for mitochondrial replication, may be inhibited by ZDV at concentrations nearer to those that can be achieved in vivo. Concerns related to the potential long-term toxicity of nucleoside analogs include potential mutagenic and carcinogenic effects, possible effects on tissues with high mitochondrial content (such as hepatic and cardiac tissue), possible teratogenicity, and possible effects on the reproductive system. ZDV has been shown to be a mutagen in vitro, and, in a mammalian in vitro cell transformation assay, ZDV was positive at concentrations of greater than or equal to 0.5 ug/mL (8). Noninvasive squamous epithelial vaginal tumors were produced after 19-21 months of continuous dosing in 12% of mice administered a dosage equivalent to three times the estimated human exposure at the recommended therapeutic dosage. Similar findings were observed in 3% of rats that received 24 times the recommended therapeutic dosage. Carcinogenicity studies in rodents, however, may not be predictive of human experience. In humans, an increased incidence of non-Hodgkin's lymphoma has been reported in HIV-infected men receiving ZDV, but this increase probably reflects longer survival despite severe immunodeficiency rather than a direct effect of ZDV (9). The potential for carcinogenesis should be further assessed through continued follow-up of children who were exposed to ZDV in utero. Myopathy and cardiomyopathy have been associated with ZDV therapy. In an individual patient, the effects secondary to ZDV are often difficult to distinguish from those of HIV infection. A prospective study of HIV- infected children demonstrated no effect of ZDV therapy on cardiac function (10). Reproductivity/fertility studies in animals have demonstrated no adverse effects of ZDV on either the fertility of male or female rats or the reproductive capacity of their offspring (11). ZDV administered to mice early in gestation was associated with an embryotoxic effect and fetal resorptions; however, ZDV administered at or beyond midgestation had no detectable effect on the fetus (12,13). ZDV is assigned pregnancy category C status by the Food and Drug Administration (FDA). ** Most studies of ZDV administered to pregnant animals have not demonstrated teratogenicity. In one study, pregnant rats were administered toxic doses of ZDV during organogenesis (i.e., equivalent to approximately 50 times the recommended daily clinical dose, based on relative body surface areas); developmental malformations and skeletal abnormalities were observed in 12% of fetuses (14). In humans, observational studies involving small numbers of subjects have demonstrated no apparent association of fetal malformations with antenatal ZDV use (15-19). In ACTG Protocol 076, the incidence of congenital malformations was similar for ZDV and placebo recipients. However, because ZDV was not administered until after 14 weeks of gestation in this study, the potential teratogenicity of ZDV administered during the first trimester cannot be assessed. Similarly, in a recent report from the Antiretroviral Pregnancy Registry maintained by the Wellcome Foundation and Hoffman LaRoche in conjunction with CDC, no increase in the risk of congenital abnormalities above that expected for all pregnancies was observed among infants born to 121 prospectively registered HIV-infected women who received ZDV during pregnancy, nor was there any unusual pattern of birth defects (20). Use of ZDV during pregnancy could be associated with the development of ZDV-resistant virus, which may lessen the drug's therapeutic benefit for the woman when it is needed for her own health. However, patients with early-stage HIV disease rarely develop ZDV-resistant strains before they have received 18-24 months of continuous therapy (21). After discontinu- ation of ZDV therapy, an increase in ZDV-susceptible isolates has been observed in some patients who had ZDV-resistant isolates while they were receiving ZDV, although resistance to ZDV has been reported to persist for more than a year after therapy was discontinued (22,23). Because the development of ZDV-resistant viral strains secondary to transient ZDV use during pregnancy is a theoretical concern, considerations for the woman's future health care should include the availability of alternative drugs for treatment of HIV infection. GENERAL PRINCIPLES REGARDING TREATMENT RECOMMENDATIONS The following treatment recommendations have been formulated to provide a basis for discussion between the woman and her health-care provider about the use of ZDV to reduce perinatal transmission. HIV-infected women should be informed of the substantial benefit and short-term safety of ZDV admin- istered during pregnancy and the neonatal period observed in ACTG Protocol 076. However, they also must be informed that the long-term risks of ZDV therapy to themselves and their children are unknown. A woman's decision to use ZDV to reduce the risk for HIV transmission to her infant should be based on a balance of the benefits and potential risks of the regimen to herself and to her child. Discussion of treatment options should be noncoercive, and the final decision to accept or reject ZDV treatment recommended for herself and her child is the right and responsibility of the woman. A decision not to accept treatment should not result in punitive action or denial of care, nor should ZDV be denied to a woman who decides to receive the regimen. Various circumstances that commonly occur in clinical practice are described and the factors influencing treatment considerations are highlighted in the following discussion (Box 3) Table_B3. All potential clinical situations cannot be enumerated, and, in many cases, definitive evidence upon which to base a recommendation is not currently available. Therefore, each pregnant woman and her health-care provider must consider the potential benefits, unknown long-term effects, and gaps in knowledge relating to her clinical situation. Furthermore, health-caregivers and institutions should provide culturally, linguistically, and educationally appropriate information and counseling to the HIV-infected woman so that she can make informed decisions. CLINICAL SITUATIONS AND RECOMMENDATIONS FOR USE OF ZDV TO REDUCE PERINATAL TRANSMISSION Clinical Situation Meeting the Entry Criteria for ACTG Protocol 076
RECOMMENDATIONS FOR MONITORING THE ZDV REGIMEN FOR MOTHERS AND INFANTS Women and their children should receive care together in a family- centered setting. Care should be coordinated between gynecologic, pedi- atric, internal medicine, infectious disease, and other health-care specialists to ensure that both mother and child receive appropriate medical follow-up. A comprehensive program of support services is necessary to ensure that both mother and child continue to receive health care. Maternal Monitoring HIV-infected pregnant women should be monitored in accordance with previously published guidelines (31,53). Monitoring during pregnancy should include monthly assessment for ZDV-associated hematologic and liver chemistry abnormalities. Indications of toxicity that might require inter- rupting or stopping the dose of ZDV include a) hemoglobin less than 8 gm/dL, b) absolute neutrophil count less than 750 cells/uL, or c) AST (SGOT) or ALT (SGPT) greater than five times the upper limit of normal. CD4+ T-lymphocyte counts should be monitored to determine if prophy- laxis for opportunistic infections, such as Pneumocystis carinii pneumonia (PCP), should be initiated. Pregnant HIV-infected women with CD4+ T-lympho- cyte counts less than 200 cells/uL should receive appropriate PCP prophy- laxis. If the CD4+ T-lymphocyte count is less than 600 cells/uL, the evaluation should be repeated each trimester. CD4+ T-lymphocyte counts should be measured at 6 weeks and 6 months postpartum to evaluate if antiretroviral therapy is indicated. Fetal Monitoring Antepartum testing, including sonographic and nonstress testing and intrapartum fetal monitoring, should be performed only as clinically indicated, not specifically because the patient is being treated with ZDV during pregnancy. Infant Monitoring A complete blood count and differential should be performed at birth as a baseline evaluation. Repeat measurements of hemoglobin are recommended at 6 and 12 weeks of age. ZDV should be administered with caution to infants born with severe anemia (hemoglobin less than 8 gm/dL), and treatment of the anemia and intensive monitoring are warranted if the drug is admin- istered. Previously published guidelines contain recommendations for diagnosing HIV infection in infants and for initiating PCP prophylaxis and antiretro- viral therapy for those who are infected (53-55). The potential efficacy of ZDV therapy for HIV-infected children who require antiretroviral therapy and who received ZDV in utero and during early infancy has not been determined. A specialist in pediatric HIV infection may be consulted if therapy is necessary for infected children whose mothers received ZDV during pregnancy. Further research is needed to describe the response to therapy and progression of disease in such infants. POTENTIAL LONG-TERM EFFECTS OF ZDV THERAPY FOR MOTHERS AND INFANTS AND RECOMMENDATIONS FOR FOLLOW-UP Discussion Observational data about the pregnancy outcomes of women who receive ZDV during pregnancy are being collected through the Antiretroviral Pregnancy Registry. The purpose of the registry is to provide surveillance for possible teratogenicity among infants born to women who received ZDV during pregnancy. Health-care providers can register such patients by calling the registry at (800) 722-9292, extension 8465, in the United States or (919) 315-8465 outside the United States. Written reports are available from Antiretroviral Pregnancy Registry, P.O. Box 12700, Research Triangle Park, NC 27709. Concerns about the potential long-term adverse effects among women include development of ZDV-resistant virus when ZDV therapy is used intermittently to reduce perinatal transmission, particularly during more than one pregnancy, and the potential effect such resistance could have on disease progression for the woman. Although results of studies have demonstrated an association between emergence of ZDV resistance and total duration of ZDV exposure, none of the study designs has specifically addressed the effect of intermittent therapy on development of resistance. Continued follow-up of the women who participated in ACTG Protocol 076 and of their infants is planned. A protocol to provide prospective evalu- ation of the health of the women enrolled in ACTG Protocol 076 is being designed by the Women's Health Committee of the ACTG. This protocol will evaluate virologic, immunologic, and clinical parameters among partici- pating women. Data are insufficient to address any effect that exposure to ZDV in utero might have on risk for neoplasia or organ system toxicities. ACTG Protocol 219 is an ongoing study designed to provide prospective evaluation for children who have been exposed through ACTG protocols to antiretroviral agents in utero or to HIV vaccines until they are 21 years of age. This protocol will provide intensive evaluation of multiple organ system functions, neuropsychologic testing, and quality of life. Information about the potential long-term effects of the complete or partial ACTG Protocol 076 ZDV regimen on women and children receiving the regimen outside a clinical trial protocol also may be provided from evaluation of federally funded and other prospective studies of HIV-infected women and their infants. Recommendation: Additional efforts are required to characterize the long-term effects of the ACTG Protocol 076 ZDV regimen on women and children. The specific issues of viral resistance and disease progression should be addressed among women who receive ZDV during pregnancy solely to reduce perinatal HIV transmission. Monitoring for these HIV-infected women should include Pap smears and gynecologic examinations as recommended in previously published guidelines (56), as well as an assessment of the patient's future needs for family planning consultation and services. Long-term follow-up of both uninfected and infected infants born to mothers receiving ZDV during pregnancy is important. Assessment of organ system toxicities, neurodevelopment, pubertal development, reproductive capacity, and development of neoplasms should be emphasized. Special studies will need to be developed to address these specific concerns, and innovative methods and support systems should be designed to assist in follow-up of these women and their children. CONCLUSION The decision by an HIV-infected pregnant woman to use ZDV to reduce the risk for perinatal transmission requires a complex balance of individual benefits and risks that is best accomplished through discussions with her health-care provider. Such discussions should be noncoercive, linguis- tically and culturally appropriate, and tailored to the patient's educa- tional level. The recommendations in this report have been developed for use in the United States. Although perinatal transmission of HIV infection is an international problem, alternative strategies may be appropriate in other countries (57). The policy and practice in other countries may differ from these recommendations and depend on local considerations, such as avail- ability of ZDV, access to facilities for intravenous infusion during labor, and alternative interventions that may be under evaluation. These recommendations have been developed in response to the urgent need to provide guidance to women and health-care providers in the United States about the use of ZDV to reduce the risk for perinatal HIV trans- mission and about the possible adverse outcomes of such ZDV treatment. They have been formulated on the basis of the available data from ACTG Protocol 076 and current information regarding factors associated with transmission. The information on which these recommendations are based is incomplete, and additional information is needed to optimize use of ZDV for this purpose. The decision to use the ACTG Protocol 076 regimen for preventing perinatal transmission of HIV requires weighing the benefits and potential risks to the HIV-infected woman and her child despite numerous uncer- tainties. Further research is a high priority and should include a) clarification of long-term risks of the ZDV regimen to the woman and/or her child, b) elucidation of the reasons for transmission despite use of the ZDV regimen, c) delineation of the relative efficacy of the various components of the ACTG Protocol 076 ZDV regimen for reducing transmission, d) evaluation of the efficacy of the regimen in women whose characteristics differ from those enrolled in ACTG Protocol 076, and e) evaluation of other interventions for preventing perinatal transmission. As further information becomes available, these recommendations may need to be modified. In addition, appropriate methods and materials should be developed for communicating treatment options, risks, and benefits to women and health- care providers so that they can make informed decisions about treatment. References
** FDA pregnancy categories are: A, in which adequate and well-controlled studies of pregnant women fail to demonstrate a risk to the fetus during the first trimester of pregnancy (and there is no evidence of a risk during later trimesters); B, in which animal reproduction studies fail to demonstrate a risk to the fetus and adequate and well- controlled studies of pregnant women have not been conducted; C, in which safety in human pregnancies has not been determined, animal studies are either positive for fetal risk or have not been conducted, and the drug should not be used unless the potential benefit outweighs the potential risk to the fetus; D, in which there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experiences, but the potential benefits from the use of the drug in pregnant women may be acceptable despite its potential risks; and X, in which studies in animals or reports of adverse reactions have indicated that the risk associated with the use of the drug for pregnant women clearly outweighs any possible benefit. +-------------------------------------------------------------------
-------+
| Erratum: Vol. 43, No. RR-11
|
|
|
| SOURCE: MMWR 43(31);575 DATE: Aug. 12, 1994
|
|
|
| In the MMWR Recommendations and Reports, "Recommendations
of |
| the U.S. Public Health Service Task Force on the Use of
Zidovudine |
| to Reduce Perinatal Transmission of Human Immunodeficiency
Virus," |
| on page i, two numerals in the telephone number for the CDC
|
| National AIDS Clearinghouse were transposed. The correct
telephone |
| number is (800) 458-5231.
|
|
|
+-------------------------------------------------------------------
-------+
===================================================================================
Box 1. Eligibility criteria for HIV-infected pregnant women participating in AIDS
Clinical Trials Group Protocol 076
o Pregnancy at 14-34 weeks of gestation.
o No antiretroviral therapy during the current pregnancy.
o No clinical indications for antenatal antiretroviral therapy.
o CD4+ T-lymphocyte count greater than or equal to 200 cells/uL at the time of
entry into the study.
===================================================================================
Return to top. Table_B2 Note: To print large tables and graphs users may have to change their printer settings to landscape and use a small font size.
===================================================================================
Box 2. Zidovudine regimen from AIDS Clinical Trials Group Protocol 076
o Oral administration of 100 mg of zidovudine (ZDV) five times daily, initiated
at 14-34 weeks of gestation and continued throughout the pregnancy.
o During labor, intravenous administration of ZDV in a 1-hour loading dose of
2 mg per kg of body weight, followed by a continuous infusion of 1 mg per kg
of body weight per hour until delivery.
o Oral administration of ZDV to the newborn (ZDV syrup at 2 mg per kg of body
weight per dose every 6 hours) for the first 6 weeks of life, beginning 8-12
hours after birth.
===================================================================================
Return to top. Table_B3 Note: To print large tables and graphs users may have to change their printer settings to landscape and use a small font size.
===================================================================================
Box 3. Summary: Clinical situations and recommendations for use of zidovudine *
to reduce perinatal HIV transmission
I. Pregnant HIV-infected women with CD4+ T-lymphocyte counts greater than or
equal to 200/uL who are at 14-34 weeks of gestation and who have no
clinical indications for ZDV and no history of extensive (greater than 6
months) prior antiretroviral therapy.
Recommendation:
The health-care provider should recommend the full ACTG Protocol 076
regimen to all HIV-infected pregnant women in this category. This recom-
mendation should be presented to the pregnant woman in the context of a
risk-benefit discussion: a reduced risk of transmission can be expected,
but the long-term adverse consequences of the regimen are not known. The
decision about this regimen should be made by the woman after discussion
with her health-care provider.
II. Pregnant HIV-infected women who are at greater than 34 weeks of
gestation, who have no history of extensive (greater than 6 months) prior
antiretroviral therapy, and who do not require ZDV for their own health.
Recommendation:
The health-care provider should recommend the full ACTG Protocol 076
regimen in the context of a risk-benefit discussion with the pregnant
woman. The woman should be informed that ZDV therapy may be less
effective than that observed in ACTG Protocol 076, because the regimen is
being initiated late in the third trimester.
III. Pregnant HIV-infected women with CD4+ T-lymphocyte counts less than
200/uL who are at 14-34 weeks of gestation, who have no other clinical
indications for ZDV, and who have no history of extensive (greater than
6 months) prior anti-retroviral therapy.
Recommendation:
The health-care provider should recommend initiation of antenatal ZDV
therapy to the woman for her own health benefit. The intrapartum and neo-
natal components of the ACTG Protocol 076 regimen should be recommended
until further information becomes available. This recommendation should
be presented in the context of a risk-benefit discussion with the
pregnant woman.
IV. Pregnant HIV-infected women who have a history of extensive (greater than
6 months) ZDV therapy and/or other antiretroviral therapy before
pregnancy.
Recommendation:
Because data are insufficient to extrapolate the potential efficacy of
the ACTG Protocol 076 regimen for this population of women, the health-
care provider should consider recommending the ACTG Protocol 076 regimen
on a case-by-case basis after a discussion of the risks and benefits with
the pregnant woman. Issues to be discussed include her clinical and immu-
nologic stability on ZDV therapy, the likelihood she is infected with a
ZDV-resistant HIV strain, and, if relevant, the reasons for her current
use of an alternative antiretroviral agent (e.g., lack of response to or
intolerance of ZDV therapy). Consultation with experts in HIV infection
may be warranted. The health-care provider should make the ACTG Protocol
076 regimen available to the woman, although its effectiveness may vary
depending on her clinical status.
V. Pregnant HIV-infected women who have not received antepartum anti-
retroviral therapy and who are in labor.
Recommendation:
For women with HIV infection who are in labor and who have not received
the antepartum component of the ACTG Protocol 076 regimen (either because
of lack of prenatal care or because they did not wish to receive
antepartum therapy), the health-care provider should discuss the benefits
and potential risks of the intrapartum and neonatal components of the
ACTG Protocol 076 regimen and offer ZDV therapy when the clinical situ-
ation permits.
VI. Infants who are born to HIV-infected women who have received no intra-
partum ZDV therapy.
Recommendation:
If the clinical situation permits and if ZDV therapy can be initiated
within 24 hours of birth, the health-care provider should offer the ACTG
Protocol 076 postpartum component of 6 weeks of neonatal ZDV therapy for
the infant in the context of a risk-benefit discussion with the mother.
Data from animal prophylaxis studies indicate that, if ZDV is adminis-
tered, therapy should be initiated as soon as possible (within hours)
after delivery. If therapy cannot begin until the infant is greater than
24 hours of age and the mother did not receive therapy during labor, no
data support offering therapy to the infant.
* These recommendations do not represent approval by the Food and Drug Adminis-
tration (FDA) or approved labeling for the particular product or indications
in question.
===================================================================================
Return to top. Disclaimer All MMWR HTML versions of articles are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the electronic PDF version and/or the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices. **Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.Page converted: 09/19/98 |
| |||||||
This page last reviewed 5/2/01
|
